A platform for research: civil engineering, architecture and urbanism
A platform for research: civil engineering, architecture and urbanism
Mitoxantrone‐Encapsulated ZIF‐8 Enhances Chemo‐Immunotherapy via Amplified Immunogenic Cell Death
https://orcid.org/0000-0003-4255-6202
AbstractChemo‐immunotherapy, combining systemic chemotherapeutic drugs and immune checkpoint blockers, is a promising paradigm in cancer treatment. However, challenges such as limited induction of immune responses and systemic immune toxicity have hindered its clinical applications. Here, a zeolite imidazolate framework‐8 (ZIF‐8) that encapsulates mitoxantrone (MIT), an immune cell death (ICD)‐inducing chemotherapeutic agent (MIT@ZIF‐8), is synthesized using a one‐pot aqueous‐phase process. ZIF‐8 serves as a dual‐functional nanomaterial for chemo‐immunotherapy: a carrier to enhance tumor uptake of MIT for improved chemotherapy efficacy, and a pyroptosis inducer to amplify MIT‐induced ICD for augmented anti‐tumor immune responses. As a result, in vivo administration of MIT@ZIF‐8 markedly inhibits tumor growth in both immunologically “hot” colon cancer and immunologically “cold” prostate cancer. Moreover, MIT@ZIF‐8 treatment increases the abundance of cytotoxic CD8+ T cells and reduces the amount of immunosuppressive regulatory T cells in tumors, thereby enhancing anti‐tumor immunity and sensitizing prostate cancer to anti‐CTLA‐4 immunotherapy. In summary, MIT@ZIF‐8 offers a highly translational approach for chemo‐immunotherapy.
Mitoxantrone‐Encapsulated ZIF‐8 Enhances Chemo‐Immunotherapy via Amplified Immunogenic Cell Death
https://orcid.org/0000-0003-4255-6202
AbstractChemo‐immunotherapy, combining systemic chemotherapeutic drugs and immune checkpoint blockers, is a promising paradigm in cancer treatment. However, challenges such as limited induction of immune responses and systemic immune toxicity have hindered its clinical applications. Here, a zeolite imidazolate framework‐8 (ZIF‐8) that encapsulates mitoxantrone (MIT), an immune cell death (ICD)‐inducing chemotherapeutic agent (MIT@ZIF‐8), is synthesized using a one‐pot aqueous‐phase process. ZIF‐8 serves as a dual‐functional nanomaterial for chemo‐immunotherapy: a carrier to enhance tumor uptake of MIT for improved chemotherapy efficacy, and a pyroptosis inducer to amplify MIT‐induced ICD for augmented anti‐tumor immune responses. As a result, in vivo administration of MIT@ZIF‐8 markedly inhibits tumor growth in both immunologically “hot” colon cancer and immunologically “cold” prostate cancer. Moreover, MIT@ZIF‐8 treatment increases the abundance of cytotoxic CD8+ T cells and reduces the amount of immunosuppressive regulatory T cells in tumors, thereby enhancing anti‐tumor immunity and sensitizing prostate cancer to anti‐CTLA‐4 immunotherapy. In summary, MIT@ZIF‐8 offers a highly translational approach for chemo‐immunotherapy.
Mitoxantrone‐Encapsulated ZIF‐8 Enhances Chemo‐Immunotherapy via Amplified Immunogenic Cell Death
https://orcid.org/0000-0003-4255-6202
AbstractChemo‐immunotherapy, combining systemic chemotherapeutic drugs and immune checkpoint blockers, is a promising paradigm in cancer treatment. However, challenges such as limited induction of immune responses and systemic immune toxicity have hindered its clinical applications. Here, a zeolite imidazolate framework‐8 (ZIF‐8) that encapsulates mitoxantrone (MIT), an immune cell death (ICD)‐inducing chemotherapeutic agent (MIT@ZIF‐8), is synthesized using a one‐pot aqueous‐phase process. ZIF‐8 serves as a dual‐functional nanomaterial for chemo‐immunotherapy: a carrier to enhance tumor uptake of MIT for improved chemotherapy efficacy, and a pyroptosis inducer to amplify MIT‐induced ICD for augmented anti‐tumor immune responses. As a result, in vivo administration of MIT@ZIF‐8 markedly inhibits tumor growth in both immunologically “hot” colon cancer and immunologically “cold” prostate cancer. Moreover, MIT@ZIF‐8 treatment increases the abundance of cytotoxic CD8+ T cells and reduces the amount of immunosuppressive regulatory T cells in tumors, thereby enhancing anti‐tumor immunity and sensitizing prostate cancer to anti‐CTLA‐4 immunotherapy. In summary, MIT@ZIF‐8 offers a highly translational approach for chemo‐immunotherapy.
Mitoxantrone‐Encapsulated ZIF‐8 Enhances Chemo‐Immunotherapy via Amplified Immunogenic Cell Death
Advanced Science
Li, Junhong (author) / Lv, Wenxing (author) / Han, Ziwei (author) / Li, Yike (author) / Deng, Jinqi (author) / Huang, Yanjuan (author) / Wan, Shuo (author) / Sun, Jiashu (author) / Dai, Bo (author)
2025-02-14
Article (Journal)
Electronic Resource
English
A Synergistic Dual‐Atom Sites Nanozyme Augments Immunogenic Cell Death for Efficient Immunotherapy
| Wiley | 2025
| Wiley | 2022